Cancer immunotherapy : nature.com subject feedshttps://www.nature.com/subjects/cancer-immunotherapy.atom2024-03-29T13:55:05+00:00Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responseshttps://www.nature.com/articles/s41598-024-57997-w2024-03-28T00:00:00+00:002024-03-28T00:00:00+00:00Zihao Wang et al.TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancershttps://www.nature.com/articles/s41586-024-07233-22024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Tushar D. Nichakawade et al.A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim resultshttps://www.nature.com/articles/s41591-024-02851-92024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Amy R. Rappaport et al.Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyhttps://www.nature.com/articles/s41467-024-46961-x2024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Filipa Lynce et al.Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancerhttps://www.nature.com/articles/s41523-024-00630-w2024-03-26T00:00:00+00:002024-03-26T00:00:00+00:00Amit A. Kulkarni et al.Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialhttps://www.nature.com/articles/s41591-024-02928-52024-03-21T00:00:00+00:002024-03-21T00:00:00+00:00Christine E. Brown et al.Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysishttps://www.nature.com/articles/s41598-024-57277-72024-03-21T00:00:00+00:002024-03-21T00:00:00+00:00Dongmei Ye et al.PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocyteshttps://www.nature.com/articles/s41551-024-01188-52024-03-21T00:00:00+00:002024-03-21T00:00:00+00:00Ruiyang Pang et al.Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challengeshttps://www.nature.com/articles/s41571-024-00882-22024-03-20T00:00:00+00:002024-03-20T00:00:00+00:00Saman Maleki Vareki et al.BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor responsehttps://www.nature.com/articles/s41596-024-00972-62024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Maria Alieva et al.Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapieshttps://www.nature.com/articles/s43018-024-00744-x2024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Anton Dobrin et al.Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapyhttps://www.nature.com/articles/s41590-024-01792-22024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Jonathan H. Chen et al.Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironmenthttps://www.nature.com/articles/s41467-024-46769-92024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Damien Maggiorani et al.A method for predicting drugs that can boost the efficacy of immune checkpoint blockadehttps://www.nature.com/articles/s41590-024-01789-x2024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Yun Xia et al.Author Correction: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationhttps://www.nature.com/articles/s41467-024-46724-82024-03-15T00:00:00+00:002024-03-15T00:00:00+00:00Celina Tretter et al.CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultshttps://www.nature.com/articles/s41375-024-02220-y2024-03-15T00:00:00+00:002024-03-15T00:00:00+00:00Liora M. Schultz et al.Proinflammatory polarization of engineered heat-inducible macrophages reprogram the tumor immune microenvironment during cancer immunotherapyhttps://www.nature.com/articles/s41467-024-46210-12024-03-15T00:00:00+00:002024-03-15T00:00:00+00:00Yanan Xue et al.Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMThttps://www.nature.com/articles/s41409-024-02269-42024-03-15T00:00:00+00:002024-03-15T00:00:00+00:00Marie Robin et al.Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim resultshttps://www.nature.com/articles/s41591-024-02893-z2024-03-13T00:00:00+00:002024-03-13T00:00:00+00:00Stephen J. Bagley et al.Multi-scale geometric network analysis identifies melanoma immunotherapy response gene moduleshttps://www.nature.com/articles/s41598-024-56459-72024-03-13T00:00:00+00:002024-03-13T00:00:00+00:00Kevin A. Murgas et al.HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in micehttps://www.nature.com/articles/s41467-024-46558-42024-03-13T00:00:00+00:002024-03-13T00:00:00+00:00Jianting Long et al.Promising dawn in tumor microenvironment therapy: engineering oral bacteriahttps://www.nature.com/articles/s41368-024-00282-32024-03-13T00:00:00+00:002024-03-13T00:00:00+00:00Zifei Wang et al.MEGA CRISPR rejuvenates exhausted CAR T cellshttps://www.nature.com/articles/d41591-024-00014-42024-03-11T00:00:00+00:002024-03-11T00:00:00+00:00Karen O’LearyNeoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trialhttps://www.nature.com/articles/s41467-024-46444-z2024-03-11T00:00:00+00:002024-03-11T00:00:00+00:00Di Wu et al.The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialhttps://www.nature.com/articles/s41467-024-46542-y2024-03-11T00:00:00+00:002024-03-11T00:00:00+00:00David Hsiehchen et al.Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyhttps://www.nature.com/articles/s41375-024-02213-x2024-03-08T00:00:00+00:002024-03-08T00:00:00+00:00Annalisa Chiappella et al.Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialhttps://www.nature.com/articles/s41591-024-02875-12024-03-07T00:00:00+00:002024-03-07T00:00:00+00:00Christine E. Brown et al.Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunityhttps://www.nature.com/articles/s41568-024-00674-x2024-03-07T00:00:00+00:002024-03-07T00:00:00+00:00Pascal Meier et al.Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapyhttps://www.nature.com/articles/s41408-024-01020-y2024-03-06T00:00:00+00:002024-03-06T00:00:00+00:00Yujie Liu et al.Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myelomahttps://www.nature.com/articles/s41467-024-46310-y2024-03-06T00:00:00+00:002024-03-06T00:00:00+00:00C. Grandclément et al.